COGNICURRENT

GLP anticipates a significant increase in rent driven by rising demand in China's logistics sector and a strategic expansion into data centers and renewable energy.

The global obesity drug market is rapidly shifting from injectable treatments to oral medications, marking a possible disruption to the dominance of Novo Nordisk and Eli Lilly.

A new study shows that patients may not experience significant weight regain after stopping GLP-1 medications like Ozempic, contrary to earlier beliefs.

The expiration of the Ozempic patent in populous countries like India and China paves the way for cheaper generic versions of GLP-1 medications, significantly impacting global health.

Experts clarify that concerns about losing muscle mass with GLP-1 weight loss treatments are more complicated than media portrayals suggest.

Reality TV star Layla Taylor discusses her struggles with an eating disorder and addiction to GLP-1 medication on 'The Secret Lives of Mormon Wives.'

The article discusses the surge in popularity of GLP-1 analog drugs, particularly semaglutide, as weight loss solutions while addressing the ethical dilemmas and social dynamics surrounding body image.

Experts warn that weight loss jabs, particularly GLP-1 inhibitors, can cause side effects in about 10% of users, making awareness of these effects crucial for potential patients.

This article discusses the significant advancements in obesity treatment, particularly focusing on GLP-1 receptor agonists, which represent a breakthrough comparable to major medical discoveries.

Lindt claims that users of weight loss drugs are purchasing more chocolate than the general population, defying previous expectations.

The use of GLP-1 medications, initially intended for diabetes treatment, is leading to reduced cravings for substances like tobacco and alcohol among some patients.

There is an increasing number of reports regarding mild side effects from medications, notably from immunosuppressants and GLP-1 receptor agonists in diabetes treatment, according to an expert from the Latvian Medicines Agency.

GLP-1 medications like Ozempic are showing promise in helping individuals overcome addictions to substances such as nicotine and alcohol without prior intent to quit.

New studies indicate that GLP-1 medications for diabetes and obesity may increase the risk of fractures and related conditions in older adults.

A majority of patients using GLP-1 injections for weight loss have successfully maintained their weight by spacing out their doses from weekly to every two or three weeks.

For the first time, patients using GLP-1 drugs for weight loss have successfully reduced their injection frequency without regaining weight, according to a report in the magazine Obesity.

An NHS doctor has warned that the 'most common' side effect of weight loss injections can be extremely uncomfortable for patients.

A study suggests that GLP-1 medications could be effective in treating and preventing addiction.

Patients using GLP-1 weight loss medications, like Wegovy and Ozempic, are experiencing a shift in how they engage with physical activity, seeing it less as a burden and more positively.

New research indicates that GLP-1 weight loss drugs may help protect the heart post-heart attack, beyond aiding in weight loss.

Research suggests that GLP-1 receptor agonists, such as Ozempic, may help prevent serious cardiac complications following heart attacks by opening previously blocked small blood vessels.

Popular weight loss medications like Ozempic and Mounjaro may help individuals avoid addiction to alcohol, tobacco, and drugs, according to a new study.

Research indicates that stopping weight loss injections can lead to significant weight regain, raising concerns about their long-term effectiveness.

The article discusses the various types of weight-loss pens, explaining how they work and the differences among them.

A study by Johns Hopkins researchers found that weight loss injections are more effective in women than in men, based on a comprehensive analysis of clinical trials.

This article discusses affordable and healthy dietary habits as alternatives to expensive weight-loss injections such as Ozempic, which are based on GLP-1 receptor activation.

The article discusses the increasing trend of purchasing weight loss medications online, particularly GLP-1 drugs, and the associated risks with unregulated sources.

A recent study has revealed a potential embarrassing side effect associated with the use of GLP-1 agonists for diabetes treatment, indicating a higher likelihood of developing chronic cough among type 2 diabetes patients compared to those on other diabetes medications.

Jon Taffer warns that increasing popularity of weight-loss drugs like GLP-1 medications is negatively impacting the restaurant industry in the US.

Recent research indicates that popular weight-loss medications can significantly influence sexual health, with mixed effects reported among users.

The experimental drug orforgliprona demonstrated greater glucose control and weight loss compared to oral semaglutide in a phase 3 study for type 2 diabetes treatment.

A new daily pill called orforglipron shows promise in helping patients lose weight, according to a clinical trial, potentially offering a non-injection alternative to existing GLP-1 medications.

Famous comedian Tanmay Bhat, who struggled with weight issues for a long time, has revealed he lost 110 kilograms and admitted to taking GLP-1 drugs for his weight loss journey.

McDonald's is observing the rising trend of weight loss medications, particularly GLP-1 injections, and their potential impact on consumer behavior before considering menu alterations in the United States.

More women are increasingly using GLP-1 receptor agonist medications known as 'slimming pens' in the postpartum period, according to a recent study.

Recent discussions about the safety of weight loss medications, particularly GLP-1 receptor agonists like Wegovy and Ozempic, have emerged due to reports of pancreatitis in some users, prompting experts to clarify the actual risks involved.

The article discusses the rise of GLP-1 medications for weight loss, highlighting their effectiveness and increased accessibility with the introduction of oral formulations.

A new AI-discovered therapy for obesity, ISM0676, presents potential advantages over existing GLP-1 receptor agonists, signifying a major shift in obesity treatment.

Weight loss pens, specifically GLP-1 agonists like Ozempic and Mounjaro, are projected to represent 20% of the revenue of major pharmacy chains in Brazil by 2030.

Researchers have found that GLP-1 weight-loss medications may increase the risk of developing scurvy, a rare disease linked to Vitamin C deficiency.

Brazilian delivery platform Shopper has launched a new category for customers using weight loss pens, featuring premium food products specifically catered to their dietary needs.

Sugar prices have plummeted to a five-year low due to weight loss drugs shifting consumer preferences toward proteins instead of sugary snacks.

The article discusses the recent advancements in obesity medications and the challenges of making them accessible to the broader population.

Many people using GLP-1 medications like Ozempic and Wegovy for weight loss are experiencing unexpected facial changes, causing concern despite their weight loss success.

Brazil's health agency issues a warning about the risk of pancreatitis associated with GLP-1 agonist medications, also known as weight loss pens, following reports of suspected deaths.

Anvisa has issued an alert about the risk of pancreatitis linked to the use of weight loss pens, following reports of six deaths associated with GLP-1 receptor antagonists.

Experts state that cases of pancreatitis linked to GLP-1 agonists used for diabetes and obesity are uncommon and should not cause alarm.

Medicines like GLP-1 have revolutionized obesity treatment, significantly impacting attitudes towards weight loss in the U.S.

Peptide therapy is gaining popularity for health and longevity, but experts caution that the hype may exceed the scientific support.

Pancreatitis cases associated with weight loss pens have surged in Brazil, prompting alerts as the issue gains international attention following a warning from the UK.